HONG KONG – Scandals continue to cast a shadow on China's vaccine industry, with Changchun Changsheng Life Sciences Ltd. recently handed a hefty fine totaling ¥9.1 billion (US$1.3 billion). Meanwhile another vaccine maker, Sinovac Biotech Ltd., has been hobbled by company infighting, which has forced it to suspend production of vaccines for hepatitis A and seasonal flu, markets for which it supplied 18 percent and 12.7 percent, respectively, of vaccine production in China last year.